COVID-SEROINDEX
DEAD

Serial Number

90089895

Owner

Kantaro Biosciences LLC

Attorney

Michelle A. Cooke

Filing Date

Aug 3, 2020

Add to watchlist:

No watchlists yet
View on USPTO

COVID-SEROINDEX Trademark

Serial Number: 90089895

COVID-SEROINDEX is a trademark filed by Kantaro Biosciences LLC on August 3, 2020. The trademark is classified under Class 1 (Chemicals). The application is currently no longer active.

Owner Contact Info

Kantaro Biosciences LLC (13 trademarks)

1460 Broadway
New York, NY 10036

Entity Type: 16

Trademark Details

Filing Date

August 3, 2020

Registration Date

Not Registered

Published for Opposition

December 21, 2021

Goods & Services

Diagnostic agents, preparations and substances other than for medical or veterinary purposes; Diagnostic preparations and reagents for scientific or medical research use; Diagnostic preparations and reagents for clinical or medical laboratory use; Diagnostic agents, preparations, substances and diagnostic test kits used for detecting and analyzing antibodies, enzymes, antigens, diseases, viruses and infections for scientific, laboratory or medical research use; Test kits consisting of diagnostic preparations, reagents, assays, solutions and buffers for clinical or medical laboratory testing and analysis of SARS-CoV-2, COVID-19, and infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Test kits comprised of diagnostic preparations, reagents and assays for testing and analysis of blood, bodily fluids, biological and cellular samples and specimens for use in infection, virus and disease detection for scientific or medical research use; Diagnostic preparations for scientific or research purposes related to vaccines in the fields of infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Diagnostic assays, media, solutions and buffers for clinical use; Diagnostic agents for carrying out serologic tests for clinical purposes; Diagnostic reagents for serologic tests of infections for clinical purposes; Diagnostic agents, preparations, substances and diagnostic test kits used for detecting antibodies, enzymes, antigens, diseases, viruses and infections for clinical and research purposes; Diagnostic preparations for clinical purposes for detecting the presence of infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; all the foregoing related to the detection, diagnosis, testing, prevention and/or treatment of SARS-CoV-2, COVID-19 and antibodies, antigens, diseases, illnesses, viruses, disorders and/or infections related to SARS-CoV-2 or COVID-19

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 19, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 19, 2022 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 15, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 21, 2021 NPUB
PUBLISHED FOR OPPOSITION
Dec 21, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 1, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 14, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 27, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 26, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 26, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 20, 2021 GNRN
NON-FINAL ACTION E-MAILED
Mar 20, 2021 GNRT
NON-FINAL ACTION WRITTEN
Mar 20, 2021 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 26, 2021 GNRN
NON-FINAL ACTION E-MAILED
Feb 26, 2021 GNRT
NON-FINAL ACTION WRITTEN
Feb 26, 2021 CNRT
ASSIGNED TO EXAMINER
Feb 10, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 1, 2020 NWOS
NEW APPLICATION ENTERED
Aug 6, 2020 NWAP